0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters |

Severe and Unrecognized Dental Abnormalities After Drug-Induced Epidermal Necrolysis FREE

Fréderick Gaultier, DDS, PhD; Juliette Rochefort, DDS; Marguerite-Marie Landru, DDS; Laurence Allanore, MD; Adrien Naveau, DDS; Jean-Claude Roujeau, MD; Bruno Gogly, DDS, PhD
Arch Dermatol. 2009;145(11):1332-1333. doi:10.1001/archdermatol.2009.233.
Text Size: A A A
Published online

Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are severe cutaneous reactions characterized by extensive apoptosis and detachment of the epithelium of skin and mucous membranes.1 Both conditions carry a high mortality rate (25%-30%) and high risk of sequelae. According to the French patients' association Amalyste (http://www.amalyste.fr/), survivors of TEN and SJS often experience dental problems that are considered by their physicians to be unrelated to the disease. We organized an oral and dental checkup of 16 patients with a history of SJS or TEN. The study was approved by the ethics committee of the French Society of Dermatology.

Patients were aged 11 to 57 years (median age, 37 years) and were examined from 1 to 36 years (median, 11 years) after diagnosis of SJS and/or TEN. The clinical examination was performed with panoramic radiography, bacteriologic analysis of periodontal pocket samples (reverse transcriptase–polymerase chain reaction), and quantitative and qualitative analysis of the saliva (viscosity, pH, and buffering capacity), which was collected by having the patient spit after 5 minutes of chewing a special wax (Saliva-Check Buffer; GC Europe NV, Leuven, Belgium). We obtained reference values for normal saliva from 12 healthy adult volunteers (controls), aged 24 to 64 years (median age, 32 years).

All patients complained of mouth discomfort. Nine had altered tongue mucosa (erythema and/or no lingual papilla) (Figure 1). Thirteen had inflammation of the gingiva; 14 had gingival recession; and 6 had gingival synechiae (Figure 2).

Place holder to copy figure label and caption
Figure 1

A patient's tongue with no lingual papilla.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2

Severe gingival and mucosal synechiae.

Graphic Jump Location

All patients had sicca syndrome (Table). Compared with controls, patients had reduced mean (SD) saliva volume (4.6 [0.8] vs 5.8 [0.5] mL), with more acid pH (6.53 [0.44] vs 7.26 [0.16]), and lower buffering capacity (8.9 [1.6] vs 11.5 [0.9] mmol/L) (Mann-Whitney P = .001 for all comparisons). Saliva viscosity was abnormal in 9 of 16 patients vs 2 of 12 controls.

Table Graphic Jump LocationTable Patient Characteristics, Clinical Features, and RT-PCR Results

Dental alterations were frequent among patients. Eleven patients had caries; 8 had at least 1 missing tooth; and 3 had severe periodontal disease. All 5 patients who contracted TEN during childhood (at ages 2.5, 5.0, 5.0, 11.0, and 11.0 years) had severe dental growth abnormalities (Table). The more severe abnormalities (dental agenesia, root dysmorphia, root-building abortion with incomplete root apex closure, shorter root, and microdontia) affected the 3 youngest patients, who each had at least 11 teeth involved (Figure 3).

Place holder to copy figure label and caption
Figure 3

Panoramic radiograph of a patient, taken at age 11 years (age of disease onset, 5 years), showing the most severe dental abnormalities. *, Root-building abortion with incomplete apex closure; #, root dysmorphia.

Graphic Jump Location

Porphyromonas gingivalis and Tannerella forsythia, 2 bacteria strongly associated with periodontitis,2 were present in 5 and 9, respectively, of the 12 tested sulcular samples (Table). Severe periodontitis was observed in 3 patients, 2 of whom tested positive for both P gingivalis and T forsythia.

Because of an obvious selection bias, low numbers, and absence of an adequate control group, this preliminary study has no epidemiologic value. Nevertheless, the frequency and homogeneity of the alterations observed are impressive, especially in younger patients, and strongly suggest the existence of dental complications of drug-induced TEN. Actually, all 16 investigated patients had at least 2 oral problems.

Sicca syndrome has been reported after TEN3 and was present in all of our patients. Quantitative and qualitative saliva alterations were probably cofactors in the pathogenesis of caries, gingival inflammation, and periodontitis,4 specifically in so far as they promoted the growth of uncommon bacterial species (ie, T forsythia and P gingivalis). These findings would suggest that patients with SJS and/or TEN might have a higher risk of periodontal disease.2

The severe tooth abnormalities observed in patients who had childhood TEN were similar to those observed after chemotherapy for cancer but with even more important damages.5 The most likely explanation is that the Hertwig epithelial root sheath, the epithelial proliferation zone of the enamel organ in a developing tooth, is affected by the acute process of apoptosis leading to the root-building abortion observed in the youngest patients.

We have to reinforce our vigilance against these severe and until recently unknown (or denied) dental consequences of SJS or TEN. Patients should be informed of the potential risk and instructed on preventive dentistry. Mouth and dental follow-up examinations should be recommended to all patients with SJS or TEN.

Correspondence: Dr Roujeau, Department of Dermatology, Hôpital Henri Mondor, LIC EA4393, Creteil, France (jean-claude.roujeau@hmm.aphp.fr).

Accepted for Publication: June 11, 2009.

Author Affiliations: Department of Odontology, Hôpital Albert Chenevier (Drs Gaultier, Rochefort, Landru, Naveau, and Gogly), and Reference Center for Toxic and Autoimmune Blistering Diseases, Department of Dermatology, Hôpital Henri Mondor (Drs Allanore and Roujeau), Créteil France.

Author Contributions: Drs Rochefort, Roujeau, and Gogly had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Roujeau and Gogly. Acquisition of data: Rochefort, Landru, and Gogly. Analysis and interpretation of data: Gaultier, Rochefort, Landru, Allanore, Naveau, Roujeau, and Gogly. Drafting of the manuscript: Gaultier, Rochefort, Naveau, Roujeau, and Gogly. Critical revision of the manuscript for important intellectual content: Landru, Allanore, and Gogly. Statistical analysis: Gaultier. Administrative, technical, and material support: Rochefort, Landru, Allanore, Naveau, Roujeau, and Gogly. Study supervision: Rochefort, Roujeau, and Gogly.

Financial Disclosure: Dr Roujeau serves as a consultant for Medimmune, Vertex, Servier, and OM-Pharma and has received research grants from Boehringer-Ingelheim, GlaxoSmithKline, Iris-Servier, Novartis, Pfizer, and Sanofi-Aventis.

Additional Contributions: Sophie Gaultier-Gaillard provided valuable help with statistical data analysis.

Becker  DS Toxic epidermal necrolysis. Lancet 1998;351 (9113) 1417- 1420
PubMed Link to Article
van Winkelhoff  AJLoos  BGvan der Reijden  WAvan der Velden  U Porphyromonas gingivalis, Bacteroides forsythus and other putative periodontal pathogens in subjects with and without periodontal destruction. J Clin Periodontol 2002;29 (11) 1023- 1028
PubMed Link to Article
Roujeau  JCPhlippoteau  CKoso  M  et al.  Sjogren-like syndrome after drug-induced toxic epidermal necrolysis. Lancet 1985;1 (8429) 609- 611
PubMed Link to Article
Márton  KBoros  IVarga  G  et al.  Evaluation of palatal saliva flow rate and oral manifestations in patients with Sjogren's syndrome. Oral Dis 2006;12 (5) 480- 486
PubMed Link to Article
Minicucci  EMLopes  LFCrocci  AJ Dental abnormalities in children after chemotherapy treatment for acute lymphoid leukemia. Leuk Res 2003;27 (1) 45- 50
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 1

A patient's tongue with no lingual papilla.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2

Severe gingival and mucosal synechiae.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3

Panoramic radiograph of a patient, taken at age 11 years (age of disease onset, 5 years), showing the most severe dental abnormalities. *, Root-building abortion with incomplete apex closure; #, root dysmorphia.

Graphic Jump Location

Tables

Table Graphic Jump LocationTable Patient Characteristics, Clinical Features, and RT-PCR Results

References

Becker  DS Toxic epidermal necrolysis. Lancet 1998;351 (9113) 1417- 1420
PubMed Link to Article
van Winkelhoff  AJLoos  BGvan der Reijden  WAvan der Velden  U Porphyromonas gingivalis, Bacteroides forsythus and other putative periodontal pathogens in subjects with and without periodontal destruction. J Clin Periodontol 2002;29 (11) 1023- 1028
PubMed Link to Article
Roujeau  JCPhlippoteau  CKoso  M  et al.  Sjogren-like syndrome after drug-induced toxic epidermal necrolysis. Lancet 1985;1 (8429) 609- 611
PubMed Link to Article
Márton  KBoros  IVarga  G  et al.  Evaluation of palatal saliva flow rate and oral manifestations in patients with Sjogren's syndrome. Oral Dis 2006;12 (5) 480- 486
PubMed Link to Article
Minicucci  EMLopes  LFCrocci  AJ Dental abnormalities in children after chemotherapy treatment for acute lymphoid leukemia. Leuk Res 2003;27 (1) 45- 50
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 3

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles